Genentech, Roches US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.
https://european-biotechnology.com/wp-content/uploads/2024/04/20160914-ac-immune.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2024-01-23 07:00:002024-07-08 15:05:57Roche jumps ship on AC Immune